| Literature DB >> 16681581 |
P W Preston1, N Hudson, F M Lewis.
Abstract
Anti-tumour necrosis factor-alpha therapy of Crohn's disease (CD) with infliximab has proved a major advance in the treatment of patients with difficult disease. We report our experience of the use of infliximab in a patient with recalcitrant vulval CD. The introduction of infliximab has improved disease control, although a search for an optimum remittive dosing schedule is ongoing.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16681581 DOI: 10.1111/j.1365-2230.2006.02079.x
Source DB: PubMed Journal: Clin Exp Dermatol ISSN: 0307-6938 Impact factor: 3.470